Study guide
2.6 Glycogen, Lipid Storage & Amino Acid Disorders
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
2.6 Glycogen, Lipid Storage & Amino Acid Disorders
Key Takeaways Explain This Topic AI
Von Gierke disease (glucose-6-phosphatase deficiency) causes fasting hypoglycaemia, lactic acidosis, hyperuricaemia and hyperlipidaemia; McArdle disease causes a second-wind phenomenon and myoglobinuria.
Fabry disease is X-linked alpha-galactosidase A deficiency causing acroparaesthesias, angiokeratoma, corneal verticillata and renal failure; Gaucher disease is the commonest sphingolipidosis.
Homocystinuria mimics Marfan syndrome but causes downward lens dislocation, learning difficulty and thromboembolism, and about half of cases respond to pyridoxine.
Last updated: September 2026
Glycogen Storage Diseases (GSDs)
Inherited enzyme deficiencies that impair glycogen synthesis or degradation, accumulating abnormal glycogen in the liver, skeletal muscle, or heart. Glycogen Degradation Pathways
- Glycogen ──(Muscle Glycogen Phosphorylase)──> Glucose-1-Phosphate [McArdle Disease]
- │
- ├──(Lysosomal Acid Alpha-Glucosidase)───> Free Glucose [Pompe Disease]
- │
- └──(Hepatic Glycogenolysis)─────────────> Glucose-6-Phosphate
- │
- ▼ (Glucose-6-Phosphatase)
- Free Glucose in Blood [Von Gierke Disease]
- Type I: Von Gierke Disease (GSD Type Ia)
Enzyme Defect : Autosomal recessive deficiency of glucose-6-phosphatase , which dephosphorylates glucose-6-phosphate to free glucose in the endoplasmic reticulum of hepatocytes and renal tubular cells.
Pathophysiology : Both glycogenolysis and gluconeogenesis are completely blocked . The liver cannot release free glucose into the systemic circulation.
Clinical & Laboratory Manifestations :
Severe Fasting Hypoglycaemia : Profound lethargy, seizures, and sweating within 2-4 hours of fasting.
Massive Hepatomegaly & Renomegaly : Due to excessive glycogen storage; spleen is normal.
Doll-Like / Cherubic Facies : Chubby cheeks caused by subcutaneous adipose deposition.
Lactic Acidosis : Glucose-6-phosphate cannot form glucose and is shunted into glycolysis, generating massive amounts of pyruvate and lactate.
Hyperuricaemia & Gout : Lactic acid competitively inhibits urate secretion at the organic anion transporter (URAT1) in renal tubules, causing severe secondary hyperuricaemia and gout.
Hyperlipidaemia : Shunting into glycerol-3-phosphate and acetyl-CoA causes striking hypertriglyceridaemia, eruptive xanthomas, and hepatic adenomas.
Glucagon Challenge Test : Administration of glucagon fails to increase blood glucose and exacerbates lactic acidosis.
Management : Frequent feeds, overnight continuous nasogastric glucose infusion or oral uncooked cornstarch.
Type II: Pompe Disease (GSD Type II)
Enzyme Defect : Autosomal recessive deficiency of lysosomal acid alpha-1,4-glucosidase (acid maltase).
Pathophysiology : Glycogen cannot be degraded within secondary lysosomes, engorging lysosomes in skeletal muscle, cardiac myocytes, and motor neurons. Cytosolic glycogenolysis is entirely intact, so blood glucose and hepatic function are completely normal .
Clinical Features : Infantile-onset form presents with massive cardiomegaly , severe hypertrophic cardiomyopathy, profound generalized hypotonia ("floppy infant"), macroglossia, respiratory distress, and death before age 1 from heart failure. Adult-onset form presents with progressive proximal myopathy and early diaphragmatic weakness.
Management : Recombinant human enzyme replacement therapy ( alglucosidase alfa ).
Type V: McArdle Disease (GSD Type V)
Enzyme Defect : Autosomal recessive deficiency of skeletal muscle glycogen phosphorylase (myophosphorylase). Hepatic phosphorylase is normal, so blood glucose is unaffected.
Pathophysiology : Skeletal myocytes cannot break down intracellular glycogen during anaerobic exertion, depriving working muscle of glucose-6-phosphate for anaerobic glycolysis.
Clinical Manifestations : Painful muscle cramping, exercise intolerance, and fatigue induced by brief bouts of high-intensity anaerobic exercise (sprinting, lifting weights). Rhabdomyolysis causes myoglobinuria (cola-colored urine; dipstick positive for blood, negative for intact RBCs on microscopy), risking acute tubular necrosis.
"Second-Wind" Phenomenon : After 8-10 minutes of rest or slow exertion, exercise tolerance dramatically improves because hepatic delivery of circulating blood glucose and free fatty acids reaches working muscle, restoring aerobic ATP production.
Diagnostic Ischemic Forearm Test : Failure of venous blood lactate to rise following ischemic forearm exercise, with a normal or exaggerated rise in blood ammonia.
Lipid Storage Diseases: The Sphingolipidoses
Sphingolipidoses are lysosomal storage disorders characterized by the progressive accumulation of unhydrolysed gangliosides, cerebrosides, or sphingomyelin within cellular lysosomes.
Disorder Inheritance Deficient Enzyme Accumulated Substrate Clinical Features & Histological Hallmarks
Gaucher Disease Autosomal Recessive Glucocerebrosidase (acid beta-glucosidase) Glucocerebroside (glucosylceramide) Massive splenomegaly, hepatomegaly, pancytopenia, bone crises, avascular necrosis of femoral head, Erlenmeyer flask deformity ; Gaucher cells (wrinkled tissue paper macrophages)
Fabry Disease X-Linked Recessive Alpha-Galactosidase A Globotriaosylceramide (Gb3 / ceramide trihexoside) Childhood acroparaesthesias , angiokeratomas (bathing trunk distribution), hypohidrosis, cornea verticillata; adult renal failure, early stroke, hypertrophic cardiomyopathy
Niemann-Pick Autosomal Recessive Sphingomyelinase Sphingomyelin Hepatosplenomegaly, cherry-red macular spot , neurodegeneration, ataxia, "foam cells" (lipid-laden vacuolated macrophages)
Tay-Sachs Autosomal Recessive Hexosaminidase A GM2 Ganglioside Cherry-red macular spot , exaggerated startle response (hyperacusis), progressive neurodegeneration, blindness; NO hepatosplenomegaly
Gaucher Disease: Detailed Clinical Features
Most prevalent lysosomal storage disease, particularly high frequency among Ashkenazi Jewish populations.
Type 1 (Non-Neuronopathic, 95% of cases) : Macrophages engulf senescent erythrocytes and leukocytes but cannot degrade glucocerebroside, transforming into Gaucher cells (engorged macrophages with striated cytoplasm resembling "wrinkled tissue paper" or "crumpled silk").
Clinical Triad : (1) Hepatosplenomegaly (massive splenomegaly causing hypersplenism), (2) Pancytopenia (thrombocytopenia leading to bruising/epistaxis, normocytic anaemia), and (3) Skeletal pathology (recurrent severe "bone crises" from bone marrow infiltration, osteopenia, osteonecrosis/avascular necrosis of the femoral heads, and pathognomonic Erlenmeyer flask deformities on plain radiographs of the distal femur).
Management : Recombinant enzyme replacement therapy ( imiglucerase , velaglucerase alfa) or substrate reduction therapy ( eliglustat , miglustat).
Fabry Disease: Detailed Clinical Features
X-linked recessive disorder caused by inactivating mutations in the GLA gene. Globotriaosylceramide (Gb3) accumulates in vascular endothelial cells, smooth muscle, renal podocytes, and cardiomyocytes.
Early Manifestations (Childhood / Adolescence) :
Acroparaesthesias : Agonizing, burning pain and dysaesthesias in the hands and feet, precipitated by fever, hot weather, exercise, or fatigue.
Angiokeratomas : Clustered, punctate, dark red to purple, non-blanching maculopapular vascular lesions located symmetrically in a "bathing trunk" distribution (umbilicus, groin, buttocks, upper thighs).
Hypohidrosis / Anhidrosis : Inability to sweat normally, predisposing to heat intolerance.
Cornea Verticillata : Whorl-like corneal opacities seen on slit-lamp biomicroscopy without visual impairment.
Late Manifestations (Adulthood, 30s-50s) :
Renal : Progressive proteinuria, glomerulosclerosis, and end-stage renal disease (ESRD).
Cardiac : Concentric left ventricular hypertrophy, conduction abnormalities, and early myocardial infarction.
Cerebrovascular : Premature ischaemic stroke and transient ischaemic attacks.
Management : Recombinant enzyme replacement ( agalsidase alfa / beta ) or pharmacological chaperone therapy ( migalastat for amenable missense mutations).
- Disorders of Amino Acid Metabolism Phenylalanine and Tyrosine Catabolism Pathways
- Phenylalanine ──(Phenylalanine Hydroxylase / BH4)──> Tyrosine ──> DOPA ──> Melanin & Catecholamines
- │ │
- └───[Block: PKU] ▼
- Homogentisic Acid
- │
- └───[Block: Alkaptonuria (HGAO)]
- ▼
- Maleylacetoacetate ──> Fumarate + Acetoacetate
- Phenylketonuria (PKU)
Enzyme Defect : Autosomal recessive deficiency of phenylalanine hydroxylase (PAH) on chromosome 12q23, which converts phenylalanine to tyrosine using tetrahydrobiopterin (BH4) as an essential cofactor. Rare variants (~2%) stem from dihydropteridine reductase (DHPR) deficiency or defective BH4 synthesis.
Pathophysiology : Unmetabolised phenylalanine accumulates to toxic concentrations in plasma and tissues, shunting into transamination products: phenylpyruvate, phenyllactate, and phenylacetate.
Clinical Manifestations (Untreated) :
Severe, irreversible intellectual disability and microcephaly.
Seizures and hyperreflexia.
Hypopigmentation : Fair skin, blonde hair, and blue eyes (phenylalanine competitively inhibits tyrosinase, impairing melanin synthesis from tyrosine).
Eczematous skin rash .
Musty / Mousy Body Odour : Imparted by phenylacetate excreted in sweat and urine.
Diagnosis : Universal newborn dried blood spot screening (tandem mass spectrometry) at day 5 of life.
Management : Lifelong dietary phenylalanine restriction, synthetic amino acid formulas enriched with tyrosine (which becomes an essential amino acid), and sapropterin (BH4 analogue) in responsive variants.
Maternal PKU Syndrome : A woman with PKU who discontinues dietary restriction before or during pregnancy exposes her developing fetus to high maternal phenylalanine (which readily crosses the placenta). Phenylalanine acts as a potent teratogen, producing microcephaly , congenital heart defects (tetralogy of Fallot, VSD), intellectual disability, and intrauterine growth restriction, regardless of the fetus's genotype.
Homocystinuria
Enzyme Defect : Autosomal recessive deficiency of cystathionine beta-synthase (CBS) on chromosome 21q22, which condenses homocysteine with serine to form cystathionine. Requires pyridoxal 5'-phosphate (vitamin B6) as a cofactor.
Pathophysiology : Severe accumulation of homocysteine and methionine in plasma and urine. Excess homocysteine reacts with reactive sulfhydryl groups, disrupting disulfide bonds and cross-linking in collagen and fibrillin-1.
Clinical Hallmarks :
Marfanoid Habitus : Tall stature, slender build, arachnodactyly, pectus excavatum or carinatum, high-arched palate, and kyphoscoliosis.
Ectopia Lentis : Subluxation of the ocular lens directed DOWNWARD and INWARD (inferonasal) . Contrast with Marfan syndrome, where ectopia lentis is UPWARD and OUTWARD (superotemporal).
Intellectual Disability & Psychiatric Disturbances : Progressive developmental delay, cognitive decline, and psychiatric symptoms (intellect is completely preserved in Marfan syndrome).
Thromboembolism : The hallmark cause of mortality! Severe, premature arterial and venous thromboembolism (deep vein thrombosis, pulmonary embolism, sagittal sinus thrombosis, stroke, and myocardial infarction) occurring in childhood, adolescence, or early adulthood due to endothelial denudation and platelet activation.
Management : High-dose oral vitamin B6 (pyridoxine) in B6-responsive CBS mutations; dietary methionine restriction supplemented with cysteine (which becomes conditionally essential); oral betaine (trimethylglycine), which provides methyl groups to remethylate homocysteine back to methionine via betaine-homocysteine methyltransferase; folic acid and vitamin B12.
Alkaptonuria
Enzyme Defect : Autosomal recessive deficiency of homogentisate 1,2-dioxygenase (HGAO) in the tyrosine and phenylalanine degradation pathway.
Pathophysiology : Homogentisic acid (HGA) accumulates in tissues and is excreted in large amounts in urine. HGA oxidises upon exposure to oxygen and light, polymerising into a dark pigment that binds irreversibly to connective tissue and fibrillar collagen ( ochronosis ).
Diagnostic Triad :
Black Urine : Urine freshly voided is normal or amber, but turns brownish-black upon standing, oxidation, or alkalinisation (e.g., addition of NaOH).
Ochronosis : Bluish-black or slate-grey pigmentation of cartilage and connective tissue, most visible in the sclerae (Osler's sign, triangular pigment spots), ear cartilage , and nasal tip.
Ochronotic Arthropathy : Premature, severe degenerative spondyloarthropathy beginning in the 30s. Pigment deposition in intervertebral discs causes disc calcification, disc space narrowing, and lumbar spine ankylosis (resembling ankylosing spondylitis, but sacroiliac joints are spared and HLA-B27 is negative). Large weight-bearing joints (knees, hips, shoulders) develop severe destructive arthritis.
Cardiovascular : Ochronotic pigment deposits in cardiac valves, causing severe aortic valve stenosis and coronary artery calcification.
Management : Symptomatic joint replacement and pain control; nitisinone (inhibits 4-hydroxyphenylpyruvate dioxygenase, the enzyme immediately upstream of HGA formation, dramatically reducing urinary HGA excretion).